Monday 1 July 2024

The Pharma Letter Podcast — Episode 16 — EQRx plots radical disruption on pricing

Biotechnology
Simon Wentworth
22 July 2022
episode16_big


More on this story...

Biotechnology
Focus on access helps EQRx find receptive audience in the UK
20 October 2021
Biotechnology
1 Year on, EQRx adds $500 million in Series B financing
11 January 2021
Biotechnology
CStone up on deal with EQRx for two immune checkpoint Inhibitors
27 October 2020
Biotechnology
EQRx gets MAA for aumolertinib accepted by EMA
2 December 2022


Related Company News

The week in pharma: action, reaction and insight – week to August 4, 2023
Revolution Medicines to acquire EQRx
EQRx ideals all but abandoned amid reset
EQRx gets MAA for aumolertinib accepted by EMA
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze